176 related articles for article (PubMed ID: 18618081)
1. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
Kindler HL; Burris HA; Sandler AB; Oliff IA
Invest New Drugs; 2009 Feb; 27(1):75-81. PubMed ID: 18618081
[TBL] [Abstract][Full Text] [Related]
2. Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells.
Li W; Su D; Mizobuchi H; Martin DS; Gu B; Gorlick R; Cole P; Bertino JR
Oncol Res; 2004; 14(7-8):373-9. PubMed ID: 15301428
[TBL] [Abstract][Full Text] [Related]
3. EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.
Batova A; Cottam H; Yu J; Diccianni MB; Carrera CJ; Yu AL
Blood; 2006 Feb; 107(3):898-903. PubMed ID: 16234352
[TBL] [Abstract][Full Text] [Related]
4. Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro.
Batova A; Diccianni MB; Omura-Minamisawa M; Yu J; Carrera CJ; Bridgeman LJ; Kung FH; Pullen J; Amylon MD; Yu AL
Cancer Res; 1999 Apr; 59(7):1492-7. PubMed ID: 10197619
[TBL] [Abstract][Full Text] [Related]
5. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells.
Hori H; Tran P; Carrera CJ; Hori Y; Rosenbach MD; Carson DA; Nobori T
Cancer Res; 1996 Dec; 56(24):5653-8. PubMed ID: 8971171
[TBL] [Abstract][Full Text] [Related]
6. Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies.
Yu J; Batova A; Shao L; Carrera CJ; Yu AL
Clin Cancer Res; 1997 Mar; 3(3):433-8. PubMed ID: 9815702
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL).
Harasawa H; Yamada Y; Kudoh M; Sugahara K; Soda H; Hirakata Y; Sasaki H; Ikeda S; Matsuo T; Tomonaga M; Nobori T; Kamihira S
Leukemia; 2002 Sep; 16(9):1799-807. PubMed ID: 12200696
[TBL] [Abstract][Full Text] [Related]
8. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
Chen ZH; Olopade OI; Savarese TM
Mol Pharmacol; 1997 Nov; 52(5):903-11. PubMed ID: 9351982
[TBL] [Abstract][Full Text] [Related]
9. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting
Hu Q; Qin Y; Ji S; Shi X; Dai W; Fan G; Li S; Xu W; Liu W; Liu M; Zhang Z; Ye Z; Zhou Z; Yang J; Zhuo Q; Yu X; Li M; Xu X
Cancer Res; 2021 Oct; 81(19):4964-4980. PubMed ID: 34385182
[TBL] [Abstract][Full Text] [Related]
10. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
Karikari CA; Mullendore M; Eshleman JR; Argani P; Leoni LM; Chattopadhyay S; Hidalgo M; Maitra A
Mol Cancer Ther; 2005 Dec; 4(12):1860-6. PubMed ID: 16373701
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.
Bertino JR; Waud WR; Parker WB; Lubin M
Cancer Biol Ther; 2011 Apr; 11(7):627-32. PubMed ID: 21301207
[TBL] [Abstract][Full Text] [Related]
12. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells.
Efferth T; Miyachi H; Drexler HG; Gebhart E
Blood Cells Mol Dis; 2002; 28(1):47-56. PubMed ID: 11987241
[TBL] [Abstract][Full Text] [Related]
13. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy.
Lubin M; Lubin A
PLoS One; 2009 May; 4(5):e5735. PubMed ID: 19478948
[TBL] [Abstract][Full Text] [Related]
14. Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.
Tang B; Testa JR; Kruger WD
Cancer Biol Ther; 2012 Sep; 13(11):1082-90. PubMed ID: 22825330
[TBL] [Abstract][Full Text] [Related]
15. Identification of gene expression profiles predicting tumor cell response to L-alanosine.
Efferth T; Gebhart E; Ross DD; Sauerbrey A
Biochem Pharmacol; 2003 Aug; 66(4):613-21. PubMed ID: 12906926
[TBL] [Abstract][Full Text] [Related]
16. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy.
Marcé S; Balagué O; Colomo L; Martinez A; Höller S; Villamor N; Bosch F; Ott G; Rosenwald A; Leoni L; Esteller M; Fraga MF; Montserrat E; Colomer D; Campo E
Clin Cancer Res; 2006 Jun; 12(12):3754-61. PubMed ID: 16778103
[TBL] [Abstract][Full Text] [Related]
17. Alanosine (UCSD).
Yu J
Curr Opin Investig Drugs; 2001 Nov; 2(11):1623-30. PubMed ID: 11763167
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of purines in human lymphoblast cells deficient in methylthioadenosine phosphorylase activity.
Gordon RB; Blackwell K; Emmerson BT
Biochim Biophys Acta; 1987 Jan; 927(1):1-7. PubMed ID: 3098299
[TBL] [Abstract][Full Text] [Related]
19. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy.
Batova A; Diccianni MB; Nobori T; Vu T; Yu J; Bridgeman L; Yu AL
Blood; 1996 Oct; 88(8):3083-90. PubMed ID: 8874207
[TBL] [Abstract][Full Text] [Related]
20. Methylthioadenosine phosphorylase deficiency in Japanese osteosarcoma patients.
Miyazaki S; Nishioka J; Shiraishi T; Matsumine A; Uchida A; Nobori T
Int J Oncol; 2007 Nov; 31(5):1069-76. PubMed ID: 17912432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
